Group 1 - The core product, TY-9591, has received acceptance for its new drug application (NDA) by the National Medical Products Administration, targeting non-small cell lung cancer brain metastases, and is the first next-generation EGFR-TKI inhibitor [1] - The estimated peak annual sales for TY-9591 in China is projected to exceed 5 billion yuan, indicating significant market potential for brain metastases and L858R mutation [1] - The Hong Kong Stock Exchange has approved the full circulation arrangement for the company's H-shares, involving the conversion of 4.608 million non-listed shares, which will enhance share liquidity [1] Group 2 - The stock price has shown volatility, closing at 12.80 HKD on February 13, 2026, a slight decrease of 0.78% from the previous close of 12.86 HKD, with a trading range of 7.52% [2] - The total trading volume from February 9 to 13, 2026, was approximately 1.038 billion HKD, with a narrowing turnover rate of 0.30% [2] - Technical indicators show improvement in short-term momentum, with the MACD histogram turning positive at 0.077 and the KDJ indicator's J line rising to 50.903 [2] Group 3 - The company's mid-2025 performance report indicates improved operational efficiency, with R&D costs reduced by 35.6% year-on-year to 88.758 million yuan, and losses narrowed by 48.79% to 112 million yuan [3] - The current revenue primarily relies on a licensing agreement with Livzon Pharmaceutical, and a commercialization team has been preliminarily established to prepare for product launches [3]
同源康医药核心产品上市申请获受理，H股全流通获批